medigraphic.com
Colegio de Medicina Interna de México.

2015, Número 5

<< Anterior Siguiente >>

Med Int Mex 2015; 31 (5)


Anticonceptivos hormonales y alteración de las pruebas de función tiroidea

Benardete-Harari DN, Navarro-Gerrard C, Meraz-Ávila D, Alkon-Meadows T, Nellen-Hummel H, Halabe-Cherem J

Idioma: Español
Referencias bibliográficas: 50
Paginas: 590-595
Archivo PDF: 414.40 Kb.


RESUMEN

El incremento del uso de anticonceptivos hormonales es cada vez más frecuente. Las pruebas de función tiroidea pueden resultar alteradas en usuarias de anticonceptivos hormonales y los tratamientos con hormonas tiroideas o antitiroideas puedes ser erróneos. Ninguna sustancia química, prescrita como medicamento, es inocua, por lo que deben considerarse los efectos secundarios de cualquier fármaco. Existen pocos estudios de los efectos adversos de los anticonceptivos hormonales y la información relacionada con su interacción en la función tiroidea es escasa.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Halabe J, Mercado M, Nellen H. Tiroides. Guía práctica para el clínico. 3ª ed. México: Manual Moderno, 2001.

  2. Braverman L. Thyroid tests. National Endocrine and Metabolic Diseases Information Service Publication, 2014. [En línea]. Dirección URL: .

  3. Guyton AC. Medical physiology. 11a ed. Philadelphia: Saunders Elsevier, 2006.

  4. Halabe-Cherem J, Nellen-Hummel H, Gordon-Barabezgzki F, Baron MA, Lifahitz-Guinzberg A. Pruebas de function tiroidea en una muestra de pacientes hospitalizados. Arch Invest Med 1989;20:327-333.

  5. Oral contraceptives and tests of thyroid function. Br Med J 1996;2:1545.

  6. Barsivala V, Virkar K. Thyroid functions of women taking oral contraceptives. Adv Plan Parent 1974;9:38-42.

  7. Djahanbakhch O, Barraclough J, Hargreaves T, Sykes DW. Thyroid function tests and oral contraceptives. Br Med J 1977;28:1413.

  8. Winikoff D, Taylor K. Oral contraceptives and thyroid function tests. Med J Aust 1966;2:108-112.

  9. Nellen-Hummel H, Halabe-Cherem J, Diaz de León-Ponce M, Lifahitz-Guinzberg A. Alteraciones en las pruebas de función tiroidea en el paciente en estado crítico. Rev Med Crit Terap Int 1990;4:28-29.

  10. Fowler MJ, Pannone AF, Blevins LS. Pitfalls to avoid while interpreting thyroid function tests: five illustrative cases. Contraception 2000;62:289-295.

  11. Halabe-Cherem J, Nellen-Hummel H, Gordon-Barabezgzki F, Lifahitz-Guinzberg A. El síndrome del eutiroideo enfermo. Gac Med Mex 1992;128:211-214.

  12. el-Mahgoub S, Karem M, Ammar R, Ghareeb A. The effects of injectable contraceptives on the direct thyroid function tests. Adv Intern Med 1972;18:345-362.

  13. Djahanbakhch O, Barraclough J, Hargreaves T, Sykes DW. Thyroid function tests and oral contraceptives. Int J Gynaecol Obstet 1977;15:35-37.

  14. Winikoff D. Oral contraceptives and thyroid function tests. The diagnosis of thyroid disease. J Periodontol 1971;42:273-275.

  15. Miller JP, Coupal JJ. Thyroid function tests: a review. Br Med J 1970;3:521.

  16. Malinek M, Winikoff D. The one-step approach to thyroid function tests. The diagnostic thyroxine ratio (DTR)/serum thyroxine (T4) level combination. Mater Med Pol 1975;7:126-132.

  17. Sterling K. Thyroid function tests. Fertil Steril 1972;23:24-28.

  18. Tata JR. Transport of thyroid hormones. Br Med Bull 1960;16:142-147.

  19. Walser HC, Margulis RR, Ladd JE. Effects of prolonged administration of progestins on the endometrium and the function of the pituitary, thyroid and adrenal glands. Int J Fertil 1964;9:189-195.

  20. Chan V, Besser GM, Landon J. Effects of oestrogen on urinary thyroxine excretion. Br Med J 1972;4:699-701.

  21. Frank P, Kay CR. Incidence of thyroid disease associated with oral contraceptives. Mod Med Asia 1978;14:7-10.

  22. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001;344:1743-1749.

  23. Frank P, Kay CR. Incidence of thyroid disease associated with oral contraceptives. Br Med J 1978;2:1531.

  24. Hollander CS, Garcia AM, Sturgis SH, Selenkow HA. Effect of an ovulatory suppressant on the serum protein-bound iodine and the red-cell uptake of radioactive tri-iodothyronine. N Engl J Med 1963;269:501-504.

  25. Larsson-Cohn U. Oral contraception and serum proteinbound iodine. Lancet 1965;1:317.

  26. Toft AD, Seth J, Kirkham KE, Marshall A, Irvine WJ. Assessment of in vitro thyroid function tests in 100 consecutive patients referred to a thyroid clinic. J Obstet Gynaecol India 1973;23:33-37.

  27. Schatz DL, Palter HC, Russell CS. Effects of oral contraceptives and pregnancy on thyroid function. Can Med Assoc J 1968;99:882-886.

  28. Toldy E, Löcsei Z, Rigó E, Kneffel P, et al. Comparative analytical evaluation of thyroid hormone levels in pregnancy and in women taking oral contraceptives: a study from an iodine deficient area. Gynecol Endocrinol 2004;18:219-226.

  29. Yazbeck CF, Sullivan SD. Thyroid disorders during pregnancy. Med Clin North Am 2012;96:235-256.

  30. Fitzpatrick DL, Russell MA. Diagnosis and management of thyroid disease in pregnancy. Obstet Gynecol Clin N Am 2010;37:173-193.

  31. Casey BM, Leveno KJ. Thyroid disease in pregnancy. Amer Colleg of Obst and Gynec N Am 2006;108:1283-1292.

  32. Toldy E, Löcsei Z, Rigó E, Kneffel P, et al. Comparative analytical evaluation of thyroid hormone levels in pregnancy and in women taking oral contraceptives: a study from an iodine deficient area. South Med J 2002;95:486-492.

  33. Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, et al. Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study. Reprod Health 2014;11:33.

  34. Saulny de Jorges J. Anticonceptivos orales. Rev Obstet Ginecol Venez 1977;37:537-552.

  35. Zanconato G, Zighelboim I, Ros A. Anticoncepción, principios científicos y prácticos. Caracas: Ediciones de la Biblioteca de la Universidad Central de Venezuela, 1988;312-318.

  36. Jutras ML. Estrogen-progestins combinations. Handbook of drug therapy in reproductive endocrinology and infertility. Boston: Little Brown and Co., 1990;44-59.

  37. Terán Dávila J, Carlos Rosales J. Una aproximación fisiopatológica y clínica al uso de anticonceptivos orales en pacientes con riesgo. Gac Md Caracas 1998;106:465-479.

  38. Koetsawang S. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. Contraception 1994;49:361-385.

  39. Sang GW. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception 1994;49:293-301.

  40. Toppozada MK1. Existing once-a-month combined injectable contraceptives. Am J Obstet Gynecol 1993;169:1540-1544.

  41. Smith MA, Youngkin EQ. Current perspectives on combination oral contraceptives. Obstet Gynecol 1984;63:764-770.

  42. Benagiano G, Primiero FM. Long acting contraceptives. Present status. J Reprod Med 1983;28:85-91.

  43. Odlind V, Weiner E, Victor A, Johansson ED. Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. J Reprod Med 1980;24:119-126.

  44. Carol W, Börner A, Klinger G, Greinke C. Transcortin as an indicator of estrogenic potency in oral contraceptives. Lipids 1980;15:39-44.

  45. Briggs M. Metabolic sequelae of oral contraceptives. Am J Obstet Gynecol 1978;132:217-219.

  46. Chang MC. Development of the oral contraceptives. Br Med J 1978;2:771-772.

  47. Weeke J, Hansen AP. Serum tsh and serum T3 levels during normal menstrual cycles and during cycles on oral contraceptives. J Bone Joint Surg Am 1975;57:657-668.

  48. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Metabolism 1971;20:878-889.

  49. Briggs MH, Briggs M. Contraceptives and serum proteins. Fertil Steril 1970;21:469-481.

  50. Tyler ET, Levin M, Elliot J, Dolman H. Present status of injectable contraceptives: results of seven-years study. Fed Proc 1970;29:1211-1219.




2020     |     www.medigraphic.com